H J Adam
Affiliation: University of Manitoba
- Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 studyHeather J Adam
Department of Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba R3A 1R9, Canada
Diagn Microbiol Infect Dis 69:307-13. 2011..9%]). The most active agents against Gram-negative bacilli were carbapenems (e.g., meropenem and ertapenem) and piperacillin-tazobactam, while for Gram-positive cocci, they were vancomycin, linezolid, and daptomycin...
- Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccinationH J Adam
Department of Microbiology, Health Sciences Centre, Winnipeg, Manitoba, Canada
Vaccine 28:4073-8. 2010..influenzae infection now commonly presents as sepsis due to non-typeable H. influenzae in older individuals. However, strain replacement of Hib with serotype f and non-typeable strains in children under 5 years was documented...
- In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolatesHeather J Adam
Department of Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A 1R9, Canada
Antimicrob Agents Chemother 53:4915-20. 2009..015 to 128; K. oxytoca, 0.5/0.06 to 1; Proteus mirabilis, 16/0.25 to > or = 512; Pseudomonas aeruginosa, 32/< or = 0.015 to > or = 512; Acinetobacter baumannii, 1/0.12 to 16)...
- Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003Kristen N Schurek
Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 5th Floor, Basic Medical Sciences Building, 730 William Avenue, Winnipeg, Manitoba, R3E 0W3, Canada
J Antimicrob Chemother 56:769-72. 2005....
- Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolatesHeather J Adam
Department of Medical Microbiology, Faculty of Medicine, University of Manitoba 730 William Avenue, Winnipeg, Manitoba, R3E 0W3, Canada
J Antimicrob Chemother 58:202-4. 2006....
- Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006Heather J Adam
Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, 730 William Ave, Winnipeg, Manitoba R3E0W3, Canada
Int J Antimicrob Agents 34:82-5. 2009..Ciprofloxacin usage appears to be the biggest driver of resistance; however, total fluoroquinolone usage is also important...
- Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005Heather J Adam
Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A 1R9, Canada
Antimicrob Agents Chemother 51:198-207. 2007..Continued surveillance and molecular analysis of fluoroquinolone-resistant S. pneumoniae in Canada are essential for appropriate empirical treatment of infections and early detection of novel resistance mechanisms...
- Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniaeKristen N Schurek
Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 5th Floor Basic Medical Sciences Building, 730 William Avenue, Winnipeg, Manitoba, Canada R3E 0W3
Int J Antimicrob Agents 28:266-9. 2006..Additionally, we propose that the use of a second fluoroquinolone marker, such as ciprofloxacin, offers the best prediction for detecting an isolate possessing a first-step parC mutation...
- Increasing genetic relatedness of ciprofloxacin-resistant Streptococcus pneumoniae isolated in Canada from 1997 to 2005Kimberly A Nichol
Diagnostic Services of Manitoba Department of Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A 1R9, Canada
Antimicrob Agents Chemother 52:1190-4. 2008..Increased genetic homogeneity among the isolates from 2003 to 2005 (cluster analysis; P < 0.001) appeared to be due to expansion of existing clonal groups and to introduction of new PFGE types...
- Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 studyKimberly A Nichol
Department of Clinical Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba R3A 1R9, Canada
Diagn Microbiol Infect Dis 69:320-5. 2011..No MRSA resistance occurred with linezolid, daptomycin, or tigecycline. In conclusion, CA-MRSA genotypes represented 25.2% of all MRSA and continue to increase in prevalence in Canadian hospitals...
- In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 studyJames A Karlowsky
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
Diagn Microbiol Infect Dis 69:342-7. 2011..Based on their robust in vitro activities, dalbavancin and telavancin have the potential to treat Gram-positive infections caused by methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae...
- Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosaGeorge G Zhanel
Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
Antimicrob Agents Chemother 50:2228-30. 2006..Antibiotic combinations using levofloxacin with any antibiotic with individual activity against P. aeruginosa resulted in synergistic lowering (an at-least-fourfold reduction) of the isolate's MPC...